StockNews.com Begins Coverage on Aeterna Zentaris (NASDAQ:AEZS)

Equities research analysts at StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research report issued on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Price Performance

NASDAQ AEZS opened at $2.72 on Friday. The company’s fifty day moving average is $2.89 and its two-hundred day moving average is $3.38. Aeterna Zentaris has a 52-week low of $3.96 and a 52-week high of $12.00. The firm has a market capitalization of $4.88 million, a price-to-earnings ratio of -0.18 and a beta of 1.55.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.